Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

Diverse epidemiological factors are associated with hepatocellular carcinoma (HCC) prevalence in different populations. However, the global landscape of the genetic changes in HCC genomes underpinning different epidemiological and ancestral backgrounds still remains uncharted. Here a collection of data from 503 liver cancer genomes from different populations uncovered 30 candidate driver genes and 11 core pathway modules. Furthermore, a collaboration of two large-scale cancer genome projects comparatively analyzed the trans-ancestry substitution signatures in 608 liver cancer cases and identified unique mutational signatures that predominantly contribute to Asian cases. This work elucidates previously unexplored ancestry-associated mutational processes in HCC development. A combination of hotspot TERT promoter mutation, TERT focal amplification and viral genome integration occurs in more than 68% of cases, implicating TERT as a central and ancestry-independent node of hepatocarcinogenesis. Newly identified alterations in genes encoding metabolic enzymes, chromatin remodelers and a high proportion of mTOR pathway activations offer potential therapeutic and diagnostic opportunities.

[1]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[2]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[3]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[4]  J. Bruix,et al.  Hepatocellular carcinoma , 2012, The Lancet.

[5]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[6]  TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL , 2014 .

[7]  Masayuki Yamamoto,et al.  Nrf2-Keap1 defines a physiologically important stress response mechanism. , 2004, Trends in molecular medicine.

[8]  Gabriele Gillessen-Kaesbach,et al.  Mutations in SRCAP, encoding SNF2-related CREBBP activator protein, cause Floating-Harbor syndrome. , 2012, American journal of human genetics.

[9]  D. Largaespada,et al.  Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR , 2013, Hepatology.

[10]  Mark Hannink,et al.  Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex , 2004, Molecular and Cellular Biology.

[11]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[12]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[13]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[14]  D. Cox,et al.  Analysis of Survival Data. , 1986 .

[15]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[16]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[17]  J. Chrivia,et al.  Human SRCAP and Drosophila melanogaster DOM Are Homologs That Function in the Notch Signaling Pathway , 2005, Molecular and Cellular Biology.

[18]  Andreas Hierholzer,et al.  Wnt/β-Catenin Signaling Regulates Telomerase in Stem Cells and Cancer Cells , 2012, Science.

[19]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[20]  Zhou Zhu,et al.  Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma , 2013, Hepatology.

[21]  Michael A Choti,et al.  Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma , 2011, Nature Genetics.

[22]  K. Hotzel,et al.  Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. , 2008, Cancer research.

[23]  Dana Pe'er,et al.  JISTIC: Identification of Significant Targets in Cancer , 2010, BMC Bioinformatics.

[24]  E. Gelmann,et al.  Silencing Mediator for Retinoid and Thyroid Hormone Receptor and Nuclear Receptor Corepressor Attenuate Transcriptional Activation by the β-Catenin-TCF4 Complex* , 2008, Journal of Biological Chemistry.

[25]  D. Agarwal,et al.  Population genetic studies on aldehyde dehydrogenase isozyme deficiency and alcohol sensitivity. , 1983, American journal of human genetics.

[26]  W. Ellis,et al.  Floating–Harbor syndrome and intramedullary spinal cord ganglioglioma: Case report and observations from the literature , 2009, American journal of medical genetics. Part A.

[27]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[28]  Y. Fong,et al.  Epidemiology and risk factors of biliary tract and primary liver tumors. , 2014, Surgical oncology clinics of North America.

[29]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[30]  C. Harley,et al.  Telomerase and cancer therapeutics , 2008, Nature Reviews Cancer.

[31]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[32]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[33]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[34]  H B El Serag.  EPIDEMIOLOGY OF VIRAL HEPATITIS AND HEPATOCELLULAR CARCINOMA , 2012 .

[35]  Jun Yu,et al.  Obesity, insulin resistance, NASH and hepatocellular carcinoma. , 2013, Seminars in cancer biology.

[36]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[37]  J. Chrivia,et al.  SNF2-related CBP activator protein (SRCAP) functions as a coactivator of steroid receptor-mediated transcription through synergistic interactions with CARM-1 and GRIP-1. , 2003, Molecular endocrinology.

[38]  P. A. Futreal,et al.  Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool , 2013, Science Translational Medicine.

[39]  Lin Li,et al.  Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma , 2013, Genome research.

[40]  Fuchu He,et al.  Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers , 2010, Nature Genetics.

[41]  M. Hashizume,et al.  Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. , 2000, Cancer research.

[42]  Yusuke Nakamura,et al.  Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma , 2011, Nature Genetics.

[43]  V. Tergaonkar,et al.  Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies. , 2014, Cancer research.

[44]  Angela M. Liu,et al.  Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma , 2012, Nature Genetics.